Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
- Authors
- Cheon, J[Cheon, Jaekyung]; Yoo, C[Yoo, Changhoon]; Hong, JY[Hong, Jung Yong]; Kim, HS[Kim, Han Sang]; Lee, DW[Lee, Dae-Won]; Lee, MA[Lee, Myung Ah]; Kim, JW[Kim, Jin Won]; Kim, I[Kim, Ilhwan]; Oh, SB[Oh, Sang-Bo]; Hwang, JE[Hwang, Jun-Eul]; Chon, HJ[Chon, Hong Jae]; Lim, HY[Lim, Ho Yeong]
- Issue Date
- Mar-2022
- Publisher
- WILEY
- Keywords
- atezolizumab; bevacizumab; hepatocellular carcinoma; neutrophil-to-lymphocyte ratio
- Citation
- LIVER INTERNATIONAL, v.42, no.3, pp.674 - 681
- Indexed
- SCIE
SCOPUS
- Journal Title
- LIVER INTERNATIONAL
- Volume
- 42
- Number
- 3
- Start Page
- 674
- End Page
- 681
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/92624
- DOI
- 10.1111/liv.15102
- ISSN
- 1478-3223
- Abstract
- Background & Aims Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III trial. Further evaluation is necessary to investigate the safety and efficacy of Ate/Bev in real settings. Methods This was a multicentre retrospective analysis. Between May 2020 and February 2021, 138 patients received Ate/Bev as first-line treatment for advanced HCC from 11 institutions. We excluded patients with Child-Pugh B or C and BCLC D stage, and the remaining 121 patients were included in this analysis. Results According to RECIST 1.1, the objective response and disease control rates were 24.0% and 76.0%. The median follow-up duration was 5.9 months (95% confidence interval [CI], 5.4-6.4), the median progression-free survival (PFS) was 6.5 months (95% CI, 4.1-9.0), and median overall survival (OS) was not reached (95% CI, not available). The most frequent grade 3-4 adverse event was aspartate aminotransferase elevation (10.7%). In the multivariate analyses, AFP increase (P = .037), baseline neutrophil-to-lymphocyte ratio (NLR) >= 5 (P = .023), and best response to stable disease or progressive disease (P = .019) were significantly associated with worse PFS. Macrovascular invasion (P = .048) and baseline NLR >= 5 (P < .001) were significantly associated with worse OS. Conclusions Ate/Bev showed real-life efficacy and safety in Korean patients with advanced HCC, in line with results from phase III trial. Considering unfavourable survival outcomes of Ate/Bev in patients with elevated NLR, careful assessment of treatment response needs to be performed in this group.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/92624)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.